• Vertex Pharmaceuticals for rare lung cancer mutations. (Like Vertex, which specializes in developing targeted therapies for a specific and rare genetic disease, ArriVent focuses on specific, uncommon EGFR mutations in lung cancer that are currently underserved.)
• A specialized AstraZeneca for underserved EGFR lung cancer. (AstraZeneca is a major player in the EGFR lung cancer space with drugs like Tagrisso, but ArriVent is laser-focused on the specific, harder-to-treat EGFR mutations that current therapies don't effectively address.)

• Furmonertinib: An investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor (TKI) primarily being developed for non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, including exon 20 insertions.
• Next-generation antibody drug conjugates: A pipeline of novel therapeutic candidates in early development aimed at treating various cancers.

Based on the provided information, ArriVent BioPharma (AVBP) is a clinical-stage biopharmaceutical company focused on the development of medicines. Its lead candidate, furmonertinib, is currently investigational and has not been approved by the U.S. Food and Drug Administration (FDA) for any use. While furmonertinib is approved and commercially distributed by Shanghai Allist Pharmaceuticals Company, Ltd. (Allist) in China, ArriVent BioPharma is in the development phase and has not yet commercialized any products in its licensed territories.

Therefore, ArriVent BioPharma does not currently have major customers for commercial product sales, as it is not actively selling or distributing approved products to other companies or individuals.

• Shanghai Allist Pharmaceuticals Company, Ltd. (688578)

Zhengbin (Bing) Yao, PhD, Chief Executive Officer

Dr. Yao is a co-founder of ArriVent BioPharma and currently serves as its Chief Executive Officer and Chairman. He is an accomplished executive and scientist with over 20 years of experience in the biotechnology and pharmaceutical industry. Previously, he co-founded Viela Bio in 2018 and served as its Chairman and CEO. Viela Bio was acquired by Horizon Therapeutics for $3.1 billion in 2021. Prior to Viela Bio, Dr. Yao held senior leadership roles at MedImmune, AstraZeneca, Genentech, Tanox (which was acquired by Genentech), Aventis, and Amgen. His experience includes leading the project team leaders group for immunology, neurosciences, virology, and metabolism at Genentech and serving as Vice President and Head of Research for Tanox. ArriVent BioPharma itself has been backed by significant investors, including Hillhouse Capital, Eli Lilly's Lilly Asia Ventures, OrbiMed, and Hongshan (formerly Sequoia China), indicating a pattern of his involvement with companies backed by prominent venture capital and private equity firms.

Winston Kung, MBA, Chief Financial Officer

Mr. Kung is the Chief Financial Officer and Treasurer of ArriVent BioPharma. He possesses over 20 years of leadership experience across life sciences and investment banking. Most recently, he served as Chief Operating Officer and Chief Financial Officer at PMV Pharmaceuticals. Prior to PMV Pharma, Mr. Kung was the Vice President of Business Development and Global Alliances at Celgene, and previously the Chief Business Officer at Celgene Cellular Therapeutics. His background also includes senior positions in global healthcare investment banking at Citigroup and Lehman Brothers, where he focused on M&A and financings. He also led multiple transactions as part of the corporate development groups at Genentech and Amgen, co-founded the Alliance Management group at Amgen, and co-led the formation of Genentech's first Corporate Venture Capital Fund.

Stuart Lutzker, MD, PhD, President, R&D

Dr. Lutzker is a co-founder of ArriVent BioPharma and serves as its President and Head of Research & Development. He brings extensive drug development experience, having previously served as Vice President and Head of Oncology, Early Clinical Development at Genentech from 2009 to 2021. At Genentech, he played a key role in the early development of multiple approved oncology drugs, including Kadcyla®, Polivy®, Venclexta®, Cotellic®, Lunsumio®, and Tecentriq®.

Robin LaChapelle, MA, Chief Operating Officer

Ms. LaChapelle is a co-founder and the Chief Operating Officer for ArriVent BioPharma. She is an accomplished executive with extensive experience in strategic planning, capital raising support, human resources assessment, executive compensation design, and executive succession planning and coaching. Prior to ArriVent, she was the Founder and Executive Director at RLT Consulting, where she advised Biopharma Chief Executive Officers and boards of directors for companies such as Viela Bio, Immunocore, and Sanofi.

Yang Wang, PhD, Chief Technology Officer

Dr. Wang serves as the Chief Technology Officer of ArriVent BioPharma, bringing over 17 years of experience in biopharmaceutical process development and commercialization. Her most recent role was Senior Vice President, Head of Chemistry, Manufacturing and Controls at Viela Bio, where she oversaw all aspects of process development, manufacturing, and supply for clinical and commercial products. Earlier, Dr. Wang was Senior Director, Analytical Sciences at Biopharmaceutical Development, MedImmune, contributing significantly to the BLA/MAA approval of three novel biologics.

The key risks to ArriVent BioPharma's business are:

1. Clinical Trial Outcomes and Regulatory Approval for Furmonertinib: The success of ArriVent BioPharma is heavily dependent on the favorable outcomes of clinical trials for its lead product candidate, furmonertinib, and its ability to secure regulatory approval from the U.S. Food and Drug Administration (FDA). Specifically, unfavorable final results from the ongoing FAVOUR trial, expected in 2024, could adversely affect the company's global pivotal Phase 3 FURVENT clinical trial plans. Furthermore, despite receiving Breakthrough Therapy Designation, this designation does not guarantee a faster development process, review, approval, or an increased likelihood of ultimate FDA approval for furmonertinib. Furmonertinib is currently only approved and commercially distributed in China, and has not been approved by the FDA for any use.

2. Dependence on a Single Lead Product Candidate: ArriVent BioPharma's current business strategy and prospects appear to be predominantly centered on the successful development and commercialization of furmonertinib. While the company aims to advance a pipeline of novel therapeutics, the detailed background information provided primarily focuses on furmonertinib, indicating a significant reliance on this single asset for its future growth and financial performance. Should furmonertinib encounter unexpected clinical or regulatory hurdles, or fail to achieve commercial success outside of greater China, the company's overall business would be substantially impacted.

ArriVent BioPharma's primary product, furmonertinib, targets specific mutations within non-small cell lung cancer (NSCLC). The addressable markets are defined by the number of patients with these mutations in regions where ArriVent BioPharma holds commercialization rights, specifically excluding Greater China (mainland China, Hong Kong, Macau, and Taiwan).

EGFR Exon 20 Insertion Mutations in NSCLC:

• In the **United States**, the annual addressable market for NSCLC patients with EGFR exon 20 insertion mutations is estimated to be approximately 1,434 patients, based on 2024 incident NSCLC cases and the prevalence of these mutations in Western populations.
• Across **EU4 (France, Germany, Italy, Spain) and the United Kingdom**, the annual addressable market for NSCLC patients with EGFR exon 20 insertion mutations is estimated to be approximately 12,871 patients, derived from the 2024 estimated EGFR-NSCLC cases and the prevalence of these mutations in EGFR-positive NSCLC in Europe.
• In **Japan**, the annual addressable market for NSCLC patients with EGFR exon 20 insertion mutations is estimated to be approximately 5,000 patients, based on 2024 estimates.
• The combined annual addressable market for EGFR exon 20 insertion mutations in the **United States, EU4, UK, and Japan** is approximately 19,305 patients.

PACC Mutations in NSCLC:

• In the **United States**, the annual addressable market for NSCLC patients with PACC mutations is estimated to be approximately 1,280 patients, based on 2024 incident NSCLC cases, the prevalence of EGFR mutations in Western populations, and PACC mutations as a percentage of EGFR mutations.
• Across **EU4 (France, Germany, Italy, Spain) and the United Kingdom**, the annual addressable market for NSCLC patients with PACC mutations is estimated to be approximately 10,550 patients, derived from the 2024 estimated EGFR-NSCLC cases and PACC mutations as a percentage of EGFR mutations.
• The combined annual addressable market for PACC mutations in the **United States, EU4, and UK** is approximately 11,830 patients.

Expected Drivers of Future Revenue Growth for ArriVent BioPharma (AVBP)

1. Commercialization of Furmonertinib for First-Line EGFR Exon 20 Insertion Mutations in the U.S.: The primary driver of revenue growth is the potential approval and subsequent commercial launch of furmonertinib for the treatment of locally advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations in the U.S. ArriVent is conducting a pivotal Phase 3 clinical trial (FURVENT) for this indication, and furmonertinib received Breakthrough Therapy Designation from the U.S. FDA in October 2023, which could expedite its development and review process.
2. Geographic Expansion of Furmonertinib Sales Globally (Excluding Greater China): ArriVent holds the exclusive rights to develop and commercialize furmonertinib worldwide, with the exception of greater China. Following initial regulatory approvals in key markets, the company is positioned to expand the drug's availability and sales into other global territories, thereby broadening its market reach and revenue generation.
3. Label Expansion of Furmonertinib to Address a Broader Range of Uncommon EGFR Mutations: ArriVent is developing furmonertinib to treat NSCLC patients across a wider array of EGFR mutations than currently served by approved EGFR TKIs. This includes preclinical activity observed in P-loop and-alpha-c-helix compressing (PACC) mutations. Successful clinical development and subsequent regulatory approvals for these additional uncommon EGFRm NSCLC indications would expand furmonertinib's target patient population and drive further revenue growth.

Share Issuance

• ArriVent BioPharma completed its Initial Public Offering (IPO) in January 2024, raising approximately $175.0 million in gross proceeds.
• The company priced an underwritten public offering of common stock and pre-funded warrants in July 2025, expecting to raise approximately $75 million in gross proceeds.

Inbound Investments

• ArriVent raised $81 million in a Series A funding round in June 2021.
• In March 2023, the company completed a $155 million oversubscribed Series B financing round.
• Total pre-IPO fundraising by March 2023 exceeded $300 million.

Outbound Investments

• In 2021, ArriVent made a $40 million upfront payment to Shanghai Allist Pharmaceuticals Company, Ltd. as part of a licensing agreement for furmonertinib.
• Approximately $5 million to $10 million from IPO proceeds were earmarked for a collaboration with Aarvik Therapeutics for a novel molecule.
• In 2025, a one-time upfront payment of $40 million was made to Lepu Biopharma Co., Ltd. for the licensing of ARR-217.

Capital Expenditures

• The company's capital allocation primarily focuses on supporting its clinical programs and pipeline development.
• Research and development expenses, which fund the advancement of drug candidates, were $79.0 million in 2024 and $153.4 million in 2025.
• Funds from equity offerings and existing cash are utilized for clinical trial execution, collaboration payments, and infrastructure necessary for operating as a public company.